Is Seres Therapeutics, Inc. (MCRB) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 111.0% / 30% | 37.3% / 30% | 5.8% / 30% | N/A | ✗ NOT HALAL |
| DJIM | 111.0% / 33% | 37.3% / 33% | 5.8% / 33% | N/A | ✗ NOT HALAL |
| MSCI | 65.5% / 33% | 22.0% / 33% | 3.4% / 33% | N/A | ✗ NOT HALAL |
| S&P | 111.0% / 33% | 37.3% / 33% | 5.8% / 33% | N/A | ✗ NOT HALAL |
| FTSE | 65.5% / 33% | 22.0% / 33% | 3.4% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | -4424.0% | |
| Net Margin | 721.9% | |
| Return on Equity (ROE) | 19.6% | |
| Return on Assets (ROA) | -42.3% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$149M |
| Free Cash Flow | -$149M |
| Total Debt | $92M |
| Debt-to-Equity | 187.6 |
| Current Ratio | 2.6 |
| Total Assets | $140M |
Price & Trading
| Last Close | $9.33 |
| 50-Day MA | $11.12 |
| 200-Day MA | $14.71 |
| Avg Volume | 68K |
| Beta | 0.3 |
|
52-Week Range
$6.53
| |
About Seres Therapeutics, Inc. (MCRB)
Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize GI pathogens, enhance GI epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation. It also develops SER-603, a LBP candidate optimized to treat disruptions in the GI microbiome and to improve GI mucosal barrier integrity through the inhibition of inflammatory bacteria and associated metabolites; and SER-147, a live biotherapeutic composition to prevent bacterial bloodstream and spontaneous bacterial peritonitis infections in patients with metabolic disease, including chronic liver disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Seres Therapeutics, Inc. (MCRB) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Seres Therapeutics, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Seres Therapeutics, Inc.'s debt ratio?
Seres Therapeutics, Inc.'s debt ratio is 111.0% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 65.5%.
What are Seres Therapeutics, Inc.'s key financial metrics?
Seres Therapeutics, Inc. has a market capitalization of $86M, trailing P/E ratio of 14.1. Return on equity stands at 19.6%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.